- Condition: Mild to Moderate Hypertension
Interventions: Drug: LCZ696; Drug: Sildenafil
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified May 2012 - Conditions: Recurrent Head and Neck Squamous Cell Carcinoma; Metastatic Head and Neck Squamous Cell Carcinoma
Interventions: Drug: BYL719+cetuximab; Drug: BYL719+cetuximab; Biological: cetuximab
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified May 2012 - Condition: Essential Hypertension
Interventions: Drug: LCZ696; Drug: Olmesartan; Drug: Placebo of LCZ696; Drug: Placebo to Olmesartan
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified May 2012 - Condition: Neuroendocrine Tumors
Intervention: Drug: RAD001
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified May 2012 - Condition: Non Familial Chylomicronemia Syndrome (Non-FCS)
Interventions: Drug: LCQ908; Drug: Fenofibrate; Drug: Fish Oil (Lovaza); Drug: Placebo of LCQ908; Drug: Placebo of fenofibrate; Drug: Placebo of fish oil
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified May 2012 - Condition: Hepatic Impairment
Intervention: Drug: LCQ908
Sponsors: Novartis; Novartis
Recruiting - verified May 2012 - Conditions: HER2 + Breast Cancer; HER2 + Gastric Cancer; Squamous Cell Carcinoma of Head and Neck
Intervention: Drug: LJM716
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified May 2012 - Condition: Proliferative Diabetic Retinopathy (PDR)
Interventions: Drug: Ranibizumab; Procedure: Laser photocoagulation; Procedure: Ranibizumab & laser photocoagulation
Sponsors: Novartis; Novartis Pharmaceuticals; Cologne Image Reading Center & Laboratory (CIRCL); Spranger Laboratories
Not yet recruiting - verified May 2012 - Condition: Branch Retinal Vein Occlusion
Interventions: Drug: Ranibizumab; Procedure: Laser
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified May 2012 - Condition: Healthy
Interventions: Drug: sotrastaurin; Drug: sotrastaurin; Drug: placebo to sotrastaurin; Drug: Avelox
Sponsors: Novartis; Novartis Pharmaceuticals
Completed - verified May 2012 - Condition: Kidney Transplant
Intervention: Drug: Everolimus
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Condition: Hypertension With Renal Dysfunction
Intervention: Drug: LCZ696
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified May 2012 - Condition: Familial Chylomicronemia Syndrome (FCS) (HLP Type I)
Intervention: Drug: LCQ908
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified April 2012 - Condition: Kidney Failure
Interventions: Drug: cyclosporin + mycophenolate mofetil; Drug: everolimus + mycophenolate mofetil
Sponsors: Centre Hospitalier Universitaire, Amiens; Centre Hospitalier Universitaire, Amiens; Novartis
Recruiting - verified May 2012 - Condition: Acute Gouty Arthritis
Interventions: Drug: ACZ885; Drug: Triamcinelone acetonide
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified May 2012 - Condition: Multiple Sclerosis
Intervention: Drug: FTY720
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified April 2012 - Condition: Alzheimer's Dementia
Intervention: Drug: ENA713
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified April 2012 - Conditions: Meningitis; Meningococcal Disease; Septicaemia
Interventions: Biological: MenACWY-CRM conjugate vaccine (Menveo, Novartis); Biological: MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) and MenACWY-CRM conjugate vaccine (Menveo, Novartis); Biological: MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) and MenACWY-CRM conjugate vaccine (Menveo, Novartis); Biological: 1/5th dose MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) and MenACWY-CRM conjugate vaccine (Menveo, Novartis)
Sponsors: University of Oxford; University of Oxford
Not yet recruiting - verified May 2012 - Condition: Multiple Sclerosis
Intervention:
Sponsors: University of Southern California; University of Southern California; Novartis Pharmaceuticals
Not yet recruiting - verified May 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Vildagliptin; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Upper Respiratory Infections
Intervention: Drug: IFF flavor 316 282, Paracetamol, Pseudoephedrine
Sponsors: Novartis; Novartis; Novartis Consumer Health
Not yet recruiting - verified April 2012 - Condition: Diabetes Mellitus, Type 2
Intervention: Drug: Vildagliptin
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified April 2012 - Condition: Retinal Vein Occlusion
Interventions: Biological: RFB002; Drug: Dexamethasone
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified April 2012 - Condition: Proliferative Diabetic Retinopathy
Intervention: Drug: CANAKINUMAB (ILARIS®)
Sponsors: Triemli Hospital; PD Dr. med. Stephan Michels; Novartis; Center for Clinical Research, University and University Hospital Zurich
Recruiting - verified April 2012 - Condition: Renal Impairment
Intervention: Drug: SOM230
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified April 2012 - Condition: Neuroendocrine Tumors
Interventions: Drug: RAD001; Drug: SOM230
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified May 2012 - Condition: Cushing's Disease
Intervention: Drug: Pasireotide sub-cutaneous formulation
Sponsors: Novartis; Novartis Pharmaceuticals
Available - verified April 2012 - Conditions: Dose Escalation; Safety; Preliminary Efficacy; Advanced Solid Tumors; Metastatic Breast Cancer; Advanced Pancreatic Adenocarcinoma; Metastatic Colorectal Cancer; Recurrent Glioblastoma Multiforme
Intervention: Drug: LDE225 and BKM120
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified May 2012 - Condition: Quality of Life
Intervention: Behavioral: Workout based on active video gaming
Sponsors: Capital District Health Authority, Canada; Capital District Health Authority, Canada; Novartis Pharmaceuticals
Not yet recruiting - verified March 2012 - Condition: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Drug: QVA149; Drug: Placebo to tiotropium; Drug: Placebo to formoterol; Drug: Tiotropium; Drug: Formoterol; Drug: Placebo to QVA149
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified April 2012 - Condition: Cold Contact Urticaria
Interventions: Drug: Omalizumab; Drug: Omalizumab; Drug: Placebo
Sponsors: Charite University, Berlin, Germany; Charite University, Berlin, Germany; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Breast Cancer
Interventions: Drug: BKM120; Drug: Paclitaxel; Drug: BKM120 matching placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified May 2012 - Condition: Lung Cancer
Intervention: Drug: LDE225, Etoposide and Cisplatin
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Condition: Hypertension
Intervention: Drug: Aliskiren
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Conditions: Adenocarcinoma, Scirrhous,; Linitis Plastica; Stomach Neoplasms,; Stomach Diseases,; Neoplasms by Site; Neoplasms
Intervention: Drug: TKI258
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified April 2012 - Condition: Parasitologically Confirmed; Malarial
Intervention: Drug: Artemether-lumefantrine combination
Sponsors: Papua New Guinea Institute of Medical Research; Papua New Guinea Institute of Medical Research; Australian Agency for International Development; National Department of Health, Papua New Guinea
Recruiting - verified May 2012 - Condition: Asthma
Interventions: Drug: VAK694; Drug: VAK694 placebo; Drug: QAX576; Drug: QAX576 placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Completed - verified March 2012 - Condition: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Drug: NVA237; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified March 2012 - Condition: Pre-eclampsia
Interventions: Drug: Placebo; Drug: RLX030
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified March 2012 - Condition: Mild and Moderate Renal Impairment
Intervention: Drug: LCZ696
Sponsors: Novartis; Novartis Pharmaceuticals
Completed - verified April 2012 - Condition: Severe Renal Impairment
Intervention: Drug: LCZ696
Sponsors: Novartis; Novartis Pharmaceuticals
Completed - verified April 2012 - Condition: Hepatic Impairment
Intervention: Drug: BAF312
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified March 2012 - Condition: Upper Respiratory Infections
Intervention: Drug: IFF flavor 316 282, Paracetamol , Phenylephrine, Guaifenesin
Sponsors: Novartis; Novartis; Novartis Consumer Health
Recruiting - verified April 2012 - Condition: Advanced Solid Tumors, Excluding Breast Cancer
Interventions: Drug: caffeine; Drug: diclofenac; Drug: omeprazole; Drug: midazolam; Drug: TKI258
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified May 2012 - Conditions: KRAS Mutated Colorectal Adenocarcinoma.; Metastatic Pancreatic Adenocarcinoma; BRAF Mutated Melanoma
Intervention: Drug: MEK162 + AMG 479
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified April 2012 - Condition: Atherosclerotic Coronary Vascular Disease
Intervention: Other: Ranolazine
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified March 2012 - Condition: End Stage Renal Disease
Intervention: Drug: Aliskiren
Sponsors: Novartis; Novartis
Completed - verified March 2012 - Condition: Allergy
Interventions: Drug: QGE031; Drug: Placebo
Sponsors: Novartis; Novartis
Recruiting - verified May 2012 - Conditions: Neuroendocrine Carcinoma of the Lung; Neuroendocrine Carcinoma of the Thymus
Interventions: Drug: Pasireotide LAR; Drug: Everolimus; Drug: Pasireotide LAR + Everolimus
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified March 2012 - Condition: Healthy
Interventions: Drug: Intranasal Oxytocin; Drug: Intranasal Vasopressin 40 or 20 units; Drug: Intranasal Vasopressin; Drug: Intranasal Placebo OT Vehicle; Drug: Intranasal Placebo Saline; Drug: Intranasal Placebo AVP Vehicle
Sponsors: Emory University; James K. Rilling, PhD; National Institute of Mental Health (NIMH)
Enrolling by invitation - verified April 2012 - Conditions: Multiple Sclerosis; Relapsing-Remitting
Intervention: Drug: Fingolimod
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified April 2012 - Conditions: Primary Myelofibrosis (PMF); Post Polycythaemia Myelofibrosis (PPV MF); Post Essential Thrombocythaemia Myelofibrosis (PET-MF)
Intervention: Drug: INC424
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified April 2012 - Condition: Cardiomegaly
Intervention: Drug: MEK162
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified March 2012 - Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: Indacaterol; Drug: Salmeterol/fluticasone
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified March 2012 - Condition: Renal Impairment
Intervention: Drug: LCQ908
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified March 2012 - Conditions: Enterocutaneous Fistulas; Intra-abdominal Infection
Interventions: Procedure: Autologous platelet-rich fibrin glue (PRFG); Drug: Octreotide
Sponsors: Jinling Hospital, China; Jinling Hospital, China
Recruiting - verified March 2012 - Condition: Asthma
Intervention: Drug: Mometasone Furoate
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified May 2012 - Condition: Tick Borne Encephalitis
Intervention: Other: Blood Sampling
Sponsors: Novartis; Novartis; Novartis Vaccines
Active, not recruiting - verified April 2012 - Condition: Diabetes Mellitus Type II
Interventions: Drug: Metformin; Drug: Metformin; Drug: Vildagliptin; Drug: Glimepiride
Sponsors: ikfe-CRO GmbH; ikfe-CRO GmbH; Novartis Pharmaceuticals; IKFE Institute for Clinical Research and Development
Recruiting - verified March 2012 - Condition: Lipid Metabolism Disorders
Interventions: Drug: Fluvastatin sodium; Drug: Fluvastatin sodium
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified March 2012 - Condition: Liver Transplantation
Interventions: Drug: Everolimus (RAD001) as add-on; Drug: tacrolimus group
Sponsors: Novartis; Novartis Pharmaceuticals; CROLLL, Winicker Norimed
Not yet recruiting - verified March 2012 - Condition: Plaque-type Psoriasis
Interventions: Drug: secukinumab 150 mg (1 injection per dose) and placebo to secukinumab 150 mg (1 injection per dose); Drug: secukinumab 150 mg (2 injections per dose); Drug: placebo to secukinumab 150 mg (2 injections per dose)
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified May 2012 - Conditions: Uveitis Related Cystoid Macular Edema; Steroid-induced Glaucoma - Borderline
Intervention: Drug: Ranibizumab
Sponsors: Moorfields Eye Hospital NHS Foundation Trust; Moorfields Eye Hospital NHS Foundation Trust; Novartis
Recruiting - verified March 2012 - Condition: Asthma
Interventions: Drug: QAW039; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified March 2012 - Condition: Chronic Heart Failure (CHF)
Interventions: Drug: RLX030; Drug: Placebo
Sponsors: Novartis; Novartis
Recruiting - verified May 2012 - Condition: Acute Heart Failure
Interventions: Drug: RLX030; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: COPD
Interventions: Drug: indacaterol; Drug: placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified February 2012 - Condition: Advanced Solid Tumor
Intervention: Drug: INC280
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Metastatic Transitional Cell Carcinoma of the Urothelium
Intervention: Drug: BKM120
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Novartis
Recruiting - verified March 2012 - Condition: Bacterial Meningitis
Intervention: Biological: Meningococcal ACWY conjugate vaccine
Sponsors: Novartis; Novartis; Novartis Vaccines
Recruiting - verified April 2012 - Condition: Type 2 Diabetes
Interventions: Drug: Metformin; Drug: vildagliptin
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified February 2012 - Condition: Multiple Myeloma
Interventions: Drug: Panobinostat; Drug: Carfilzomib
Sponsors: Emory University; Emory University; Multiple Myeloma Research Consortium; Novartis; Onyx Therapeutics, Inc.
Recruiting - verified March 2012 - Condition: Hypertension
Intervention: Drug: Valsartan
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Conditions: Renal Function; Liver Transplant
Intervention: Drug: Introduction of everolimus with reduced cyclosporine or tacrolimus dose, the earliest 1 month and the latest 6 months after liver transplantation.
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified May 2012 - Condition: Moderate to Severe Plaque-type Psoriasis
Interventions: Drug: Secukinumab (AIN457); Drug: Placebo
Sponsors: Novartis; Novartis
Not yet recruiting - verified April 2012 - Condition: Psoriasis
Intervention: Drug: BCT194
Sponsors: Novartis; Novartis Pharmaceuticals
Completed - verified February 2012 - Condition: Scleroderma
Interventions: Drug: Imatinib mesylate; Other: Placebo
Sponsors: Lawson Health Research Institute; Lawson Health Research Institute; Novartis Pharmaceuticals
Terminated - verified March 2012 - Conditions: Neurogenic Urinary Bladder; Neurogenic Bladder Disorder; Neurogenic Dysfunction of the Urinary Bladder; Neurogenic Bladder, Uninhibited; Neurogenic Bladder, Spastic
Interventions: Drug: Investigational new drug company code: SAF312 placebo; Drug: Investigational new drug company code: SAF312
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Condition: Psoriasis, Plaque-type Psoriasis
Interventions: Drug: secukinumab; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Conditions: Macular Edema; Central Retinal Vein Occlusion
Intervention: Drug: Ranibizumab 0.5 mg/0.05 ml, intravitreal injection
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified March 2012 - Conditions: Cryopyrin-associated Periodic Syndromes; Familial Cold Autoinflammatory Syndrome; Muckle-Wells Syndrome; Neonatal Onset Multisystem Inflammatory Disease
Intervention: Biological: ACZ885
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Skeletal Muscle
Interventions: Drug: BYM338; Drug: Placebo
Sponsors: Novartis; Novartis
Recruiting - verified May 2012 - Conditions: Neovascular Age-elated Macular Degeneration (Wet AMD); Exudative Macular Degeneration
Interventions: Drug: LFG316; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified March 2012 - Condition: Relapsing Remitting Multiple Sclerosis
Interventions: Drug: Fingolimod 0.5 mg/day per os; Drug: Interferon β- 1a
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified February 2012 - Condition: Pulmonary Arterial Hypertension
Interventions: Drug: Nilotinib; Drug: Matching placebo to Nilotinib
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified February 2012 - Condition: Alzheimer's Disease
Intervention: Drug: Rivastigmine transdermal patch
Sponsors: Novartis; Novartis Pharmaceuticals; Ono Pharma
Not yet recruiting - verified March 2012 - Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: QVA149; Drug: NVA237; Drug: QAB149; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified February 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Placebo of vildagliptin; Drug: vildagliptin; Drug: Metformin
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified March 2012 - Condition: Depression
Intervention: Drug: ABP688
Sponsors: Novartis; Novartis Pharmaceuticals
Completed - verified February 2012 - Conditions: Chronic Kidney Disease; Proteinuria
Intervention: Drug: aliskiren, eplerenon, telmisartan
Sponsors: Medical University of Gdansk; Medical University of Gdansk
Completed - verified February 2012 - Conditions: Pertussis; Whooping Cough; Tetanus; Lockjaw; Diphtheria
Intervention: Biological: Acellular Pertussis and Acellular Pertussis in combination with Tetanus and Diphtheria booster vaccine
Sponsors: Novartis; Novartis Vaccines
Recruiting - verified May 2012 - Condition: Solid Tumors Harboring a BRAF V600 Mutation
Interventions: Drug: LGX818; Drug: MEK162
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified April 2012 - Condition: Advanced Solid Tumors
Intervention: Drug: TAS266
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified May 2012 - Conditions: Multifocal Choroiditis; Panuveitis; Active Vitritis
Interventions: Drug: LFG316; Other: Conventional Therapy
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified May 2012 - Condition: Hepatic Impairment
Intervention: Drug: AGO178
Sponsors: Novartis; Novartis Pharmaceuticals; Servier
Completed - verified February 2012 - Conditions: Geographic Atrophy; Age-related Macular Degeneration
Interventions: Drug: LFG316; Drug: Sham
Sponsors: Novartis; Novartis
Recruiting - verified February 2012 - Condition: Metastatic Breast Cancer
Interventions: Drug: Dovitinib; Drug: Fulvestrant
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Malaria
Interventions: Drug: KAE609; Drug: KAE609
Sponsors: Novartis; Novartis
Recruiting - verified January 2012 - Condition: Chronic Idiopathic Urticaria
Interventions: Drug: IGE025; Drug: Placebo to IGE025
Sponsors: Novartis; Novartis
Recruiting - verified May 2012 - Conditions: Pulmonary Infections; Pseudomonas Aeruginosa in Cystic Fibrosis
Intervention: Drug: Tobramycin inhalation powder
Sponsors: Novartis; Novartis
Recruiting - verified January 2012 - Condition: Atopic Dermatitis
Interventions: Biological: QGE031; Drug: Placebo; Drug: Cyclosporine A
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified March 2012 - Condition: Acute Coronary Syndromes
Interventions: Drug: Everolimus; Drug: Placebo
Sponsors: University of Zurich; University of Zurich; Swiss National Science Foundation; Novartis
Not yet recruiting - verified February 2012 - Condition: Type 2 Diabetes
Interventions: Drug: Vildagliptin/ Metformin; Drug: Liraglutide; Drug: Metformin
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified January 2012 - Condition: Metastatic Gastric Cancer
Intervention: Drug: Panobinostat (LBH589)
Sponsors: Technische Universität München; Technische Universität München; Novartis
Recruiting - verified May 2011 - Condition: Acute Lymphoblastic Leukemia
Interventions: Drug: Everolimus; Drug: Prednisone; Drug: Vincristine; Drug: PEG-Asparaginase; Drug: Doxorubicin; Drug: Dexrazoxane
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Novartis
Recruiting - verified January 2012 - Condition: Metastatic Renal Cell Carcinoma (mRCC)
Intervention: Drug: Everolimus
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified May 2012 - Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: NVA237 50µg once daily; Drug: Tiotropium 18µg once daily; Drug: Placebo; Drug: Fluticasone/Salmeterol
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Condition: Eating Behavior
Interventions: Drug: Oxytocin; Drug: Placebo
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Recruiting - verified April 2012 - Daptomycin Versus Vancomycin in the Treatment of Nosocomial or Healthcare-associated MRSA BacteremiaConditions: Nosocomial Infection; Healthcare-associated Infection
Interventions: Drug: vancomycin monotherapy; Drug: daptomycin monotherapy
Sponsors: Assistance Publique - Hôpitaux de Paris; Assistance Publique - Hôpitaux de Paris; Novartis
Not yet recruiting - verified December 2011 - Condition: Adenoid Cystic Carcinoma
Intervention: Drug: Dovitinib (TKI258)
Sponsors: University of Virginia; University of Virginia; Novartis Pharmaceuticals
Recruiting - verified March 2012 - Condition: Fed
Intervention: Drug: Amlodipine Besylate/Benazepril HCl
Sponsors: Dr. Reddy's Laboratories Limited; Dr. Reddy's Laboratories Limited
Completed - verified January 2012 - Condition: Fasting
Intervention: Drug: Amlodipine Besylate/Benazepril HCl
Sponsors: Dr. Reddy's Laboratories Limited; Dr. Reddy's Laboratories Limited
Completed - verified January 2012 - Condition: Cancer
Interventions: Drug: BEZ235; Drug: Everolimus
Sponsors: University of Cincinnati; University of Cincinnati; Novartis
Recruiting - verified January 2012 - Condition: Hepatitis C
Intervention: Drug: Alisporivir
Sponsors: Novartis; Novartis Pharmaceuticals
Terminated - verified May 2012 - Conditions: Advanced NET of GI Origin; Advanced NET of Lung Origin; Neuroendocrine Tumors
Interventions: Drug: Everolimus; Drug: Everolimus Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Conditions: Healthy; Psoriasis
Intervention: Drug: secukinumab (AIN457)
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified February 2012 - Condition: Familial Chylomicronemia Syndrome (FCS)
Interventions: Drug: LCQ908; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified May 2012 - Condition: Relapsing Remitting Multiple Sclerosis
Intervention: Drug: Fingolimod (FTY720)
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified February 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Vildagliptin; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified January 2012 - Condition: BRAF Mutant Metastatic Melanoma
Intervention: Drug: BKM120 Combined with Vemurafenib (PLX4032)
Sponsors: University of California, San Francisco; University of California, San Francisco; Novartis
Not yet recruiting - verified January 2012 - Condition: Healthy
Interventions: Drug: CJ Amlodipine/Valsartan 10/160mg; Drug: Novartis Exforge 10/160mg
Sponsors: CJ Cheiljedang Corporation; CJ Cheiljedang Corporation
Completed - verified April 2012 - Conditions: Lung Cancer; Breast Cancer; Colorectal Cancer; Cholangiocarcinoma; Solid Tumors
Intervention: Drug: BKM120
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Conditions: Myelofibrosis; Post Polycythemia Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis
Intervention: Drug: INC424
Sponsors: Novartis; Novartis Pharmaceuticals
Available - verified December 2011 - Condition: Metastatic Renal Cell Carcinoma
Intervention: Drug: Everolimus
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Conditions: Dyskinesias; Parkinson Disease; Movement Disorders; Parkinsonian Disorders; Anti-Dyskinesia Agents
Interventions: Drug: AFQ056; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Adrenocortical Carcinoma
Intervention: Drug: Dovitinib
Sponsors: Spanish Oncology Genito-Urinary Group; Spanish Oncology Genito-Urinary Group
Not yet recruiting - verified January 2012 - Condition: Fatigue in Multiple Sclerosis
Intervention: Drug: Physical exercise
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified March 2012 - Condition: Breast Cancer
Interventions: Drug: BKM120; Drug: BEZ235
Sponsors: Grupo Hospital de Madrid; Sofia Perea, PharmD, PhD; Novartis
Not yet recruiting - verified January 2012 - Condition: Multiple Sclerosis
Intervention: Drug: Fingolimod
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Pancreatic Cancer
Intervention: Drug: LDE225+gemcitabine
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Conditions: Recurrent Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer
Interventions: Drug: erlotinib hydrochloride; Drug: dovitinib lactate
Sponsors: Stanford University; Heather Wakelee; National Cancer Institute (NCI); Novartis
Not yet recruiting - verified January 2012 - Condition: Multiple Myeloma
Interventions: Drug: Phase I Dose level -1; Carfilzomib and panobinstat; Drug: Phase I Dose Level 1, Carfilzomib and Panobinostat; Drug: Phase I Dose Level 2; carfilzomib and panobinostat; Drug: Phase 1 Dose level 3; carfilzomib and panobinostat; Drug: Phase I dose level 4; carfilzomib and panobinostat; Drug: Phase II Dose Level TBD; carfilzomib and panobinostat
Sponsors: Sarah Cannon Research Institute; Sarah Cannon Research Institute; Onyx Therapeutics, Inc.; Novartis
Recruiting - verified January 2012 - Conditions: Breast Neoplasms; Endocrine Breast Diseases; Neoplasm Metastasis
Interventions: Drug: letrozole; Drug: lapatinib; Drug: everolimus
Sponsors: University of Maryland; University of Maryland; Novartis Pharmaceuticals; GlaxoSmithKline
Not yet recruiting - verified December 2011 - Conditions: Dyskinesias; Parkinson Disease; Movement Disorders; Parkinsonian Disorders; Anti-Dyskinesia Agents
Intervention: Drug: AFQ056
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Conditions: Solid Tumors; Bladder Cancer
Interventions: Drug: Gemcitabine + Cisplatin + Dovitinib; Drug: Gemcitabine + Carboplatin + Dovitinib
Sponsors: Mount Sinai School of Medicine; Matthew Galsky; Novartis
Recruiting - verified March 2012 - Condition: Gastrointestinal Stromal Tumors
Intervention: Drug: imatinib mesylate
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Conditions: Dyslipidemia; Healthy Volunteers
Intervention: Drug: TAP311
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Non Small Cell Lung Cancer
Interventions: Drug: BKM120; Drug: Erlotinib
Sponsors: Sarah Cannon Research Institute; Sarah Cannon Research Institute; Novartis
Not yet recruiting - verified March 2012 - Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular CarcinomaCondition: Advanced Adult Hepatocellular Carcinoma
Interventions: Drug: Everolimus; Drug: Pasireotide
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center; Novartis Pharmaceuticals
Recruiting - verified March 2012 - Conditions: Meningococcal Disease,; Meningococcal Meningitis,; Prevention Vaccination
Intervention: Biological: Recombinant Meningococcal B + Outer Membrane Vesicle New Zealand Vaccine
Sponsors: Novartis; Novartis Vaccines
Not yet recruiting - verified May 2012 - Condition: Delirium
Interventions: Drug: Rivastigmine transdermal patch; Drug: placebo patch
Sponsors: Assistance Publique - Hôpitaux de Paris; Assistance Publique - Hôpitaux de Paris; Novartis Pharmaceuticals
Recruiting - verified November 2011 - Condition: Asthma
Interventions: Drug: QBX258; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Condition: Fragile X Syndrome
Intervention: Drug: AFQ056
Sponsors: Novartis; Novartis
Not yet recruiting - verified November 2011 - Conditions: Type 1 Diabetes; Insulin Dependent Diabetes; Juvenile Onset Diabetes Mellitus; Autoimmune Diabetes
Intervention: Drug: Vildagliptin
Sponsors: Federal University of São Paulo; Federal University of São Paulo; Novartis
Not yet recruiting - verified March 2012 - Condition: Breast Cancer
Interventions: Drug: Dovitinib; Drug: Aromatase Inhibitors
Sponsors: Georgetown University; Georgetown University; Novartis Pharmaceuticals
Active, not recruiting - verified November 2011 - Condition: Asthma
Interventions: Drug: AIN457 (secukinumab); Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Condition: Lymphoma
Intervention: Drug: AUY922
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Novartis
Not yet recruiting - verified May 2012 - Condition: Gastrointestinal Stromal Tumors
Intervention: Drug: Dovitinib (TKI258)
Sponsors: Novartis; Novartis
Not yet recruiting - verified November 2011 - Condition: Asthma
Interventions: Drug: Indacaterol Maleate (high dose; Form 1) and Placebo (Form 2); Drug: Placebo (Form 1) and Indacaterol Maleate (high dose; Form 2); Drug: Placebo (Form 1) and Indacaterol Maleate (low dose; Form 2); Drug: Placebo (Form 1) and Placebo (Form 2)
Sponsors: Novartis; Novartis
Recruiting - verified December 2011 - Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: QVA149; Drug: Tiotropium; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Active, not recruiting - verified April 2012 - Conditions: Acute Myelocytic Leukemia; Acute Lymphocytic Leukemia; Chronic Myelogenous Leukemia; Myelodysplastic Syndrome; Chronic Lymphocytic Leukemia; Marginal Zone Lymphoma; Follicular Lymphomas; Large-cell Lymphoma; Lymphoblastic Lymphoma; Burkitt's Lymphoma; High Grade Lymphomas; Mantle-cell Lymphoma; Lymphoplasmacytic Lymphoma
Intervention: Biological: HSC835
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified November 2011 - Condition: Iron Overload
Intervention: Drug: Desferasirox
Sponsors: Novartis; Novartis
Recruiting - verified March 2012 - Condition: Advanced Solid Tumors
Intervention: Drug: TKI258
Sponsors: Novartis; Novartis Pharmaceuticals
Active, not recruiting - verified November 2011 - Conditions: Coronary Artery Disease; Hypertriglyceridemia
Interventions: Drug: LCQ908; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified January 2012 - Condition: Advanced Solid Tumor
Intervention: Drug: MEK162
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: 3rd Line GIST
Intervention: Drug: STI571 + BKM120
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified April 2012 - Condition: Acute Myeloid Leukemia
Interventions: Drug: Midostaurin; Drug: Cytarabine; Drug: Daunorubicin
Sponsors: University of Ulm; University of Ulm; Novartis Pharmaceuticals
Not yet recruiting - verified February 2012 - Conditions: Meningococcal Disease; Meningococcal Meningitis; Typhoid; Yellow Fever; Rabies; Japanese Encephalitis
Interventions: Biological: MenACWY-CRM; Biological: Typhoid Vi Polysaccharide Vaccine; Biological: Live attenuated, Yellow fever virus-17D-204 strain; Biological: Inactivated, adsorbed Japanese encephalitis Vaccine; Biological: Inactivated, Rabies Vaccine
Sponsors: Novartis; Novartis; Novartis Vaccines
Active, not recruiting - verified March 2012 - Conditions: Diphtheria,; Tetanus,; Pertussis,; Hepatitis B,; Hemophilus Influenzae B
Intervention: Biological: DTwP-HepB-Hib Vaccine
Sponsors: Novartis; Novartis Vaccines
Completed - verified April 2012 - Condition: Hypertension
Interventions: Dietary Supplement: Vitamin D (cholecalciferol); Drug: Tekturna(Aliskiren) plus placebo
Sponsors: Wayne State University; Wayne State University; Novartis
Recruiting - verified November 2011 - Conditions: Adenocarcinoma of the Pancreas; Metastatic Disease
Intervention: Drug: AUY922
Sponsors: University Health Network, Toronto; University Health Network, Toronto; Novartis Pharmaceuticals
Not yet recruiting - verified January 2012 - Conditions: Hypertension; Diabetes
Interventions: Drug: Aliskiren vs. hydrochlorothiazide; Drug: Hydrochlorothiazide
Sponsors: Sir Mortimer B. Davis - Jewish General Hospital; Sir Mortimer B. Davis - Jewish General Hospital; Novartis Pharmaceuticals
Suspended - verified January 2012 - Condition: Cystic Fibrosis
Intervention:
Sponsors: Novartis; Novartis Pharmaceuticals
Active, not recruiting - verified October 2011 - Condition: Cystic Fibrosis
Interventions: Drug: Tobramycin solution for inhalation; Drug: Aztreonam lysine for inhalation
Sponsors: Novartis; Novartis Pharmaceuticals
Completed - verified October 2011 - Condition: Asthma
Intervention:
Sponsors: Novartis; Novartis Pharmaceuticals
Active, not recruiting - verified October 2011 - Condition: Renal Transplantation
Interventions: Drug: Basiliximab; Drug: Basiliximab; Drug: Basiliximab
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified March 2012 - Condition: End Stage Liver Disease
Intervention:
Sponsors: The Methodist Hospital System; R. Mark Ghobrial, MD; Novartis
Enrolling by invitation - verified October 2011 - Effect of Switching to Certican® in Viremia of Hepatitis C Virus in Adult Renal Allograft RecipientsConditions: Renal Allograft; Hepatitis C
Interventions: Drug: Everolimus; Drug: Cyclosporine; Drug: Tacrolimus
Sponsors: Irmandade Santa Casa de Misericórdia de Porto Alegre; Irmandade Santa Casa de Misericórdia de Porto Alegre; NOVARTIS BIOCIÊNCIAS S.A.
Recruiting - verified January 2012 - Condition: Major Depressive Disorder
Interventions: Drug: Iloperidone; Drug: Placebo
Sponsors: Massachusetts General Hospital; Maurizio Fava, MD; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Osteo Arthritis of the Knee
Interventions: Drug: Diclofenac; Drug: Placebo
Sponsors: Anchen Pharmaceuticals, Inc; Anchen Pharmaceuticals, Inc; Novum Pharmaceutical Research Services
Active, not recruiting - verified March 2012 - Conditions: Acute Myeloid Leukemia; Advanced Myelodysplastic Syndrome
Interventions: Drug: Panobinostat; Drug: Cytarabine; Drug: Daunorubicin
Sponsors: University of California, San Francisco; C. Babis Andreadis; University of California, San Francisco; Novartis
Recruiting - verified March 2012 - Condition: Philadelphia Chromosome Positive Chronic Myelogenous Leukemia
Intervention: Drug: Nilotinib + LDE225
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Conditions: Esophageal Cancer; Neoplasms, Esophageal
Interventions: Drug: Everolimus; Drug: Paclitaxel; Drug: carboplatin; Drug: cetuximab
Sponsors: Emory University; Emory University; Novartis
Recruiting - verified March 2012 - Condition: Solid Tumors
Intervention: Drug: BKM120 and RAD001
Sponsors: Emory University; Emory University; Novartis Pharmaceuticals
Recruiting - verified February 2012 - Condition: Multiple Myeloma
Intervention: Drug: LGH447
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Condition: Peanut Allergy
Interventions: Drug: QGE031; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified March 2012 - Conditions: Locally Advance Breast Cancer (LABC); Metastatic Breast Cancer (MBC)
Interventions: Drug: BEZ235 + Trastuzumab Phase l/Phase ll); Drug: Lapatinib + Capecitabine (Phase II)
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Advanced and Selected Solid Tumors
Intervention: Drug: BYL719 plus MEK162
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Condition: Type 2 Diabetes
Intervention:
Sponsors: Foundation for the National Institutes of Health; Foundation for the National Institutes of Health; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Juvenile Diabetes Research Foundation; Amylin Pharmaceuticals, Inc.; Merck; Pfizer; Eli Lilly and Company; Takeda Global Research & Development Center, Inc.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Novartis
Recruiting - verified October 2011 - Conditions: Meningococcal Disease; Meningococcal Meningitis; Hepatitis A; Hepatitis B
Interventions: Biological: MenACWY-CRM; Biological: Combined inactivated hepatitis A and recombinant hepatitis B vaccine; Biological: Recombinant hepatitis B vaccine; Biological: Inactivated hepatitis A vaccine
Sponsors: Novartis; Novartis; Novartis Vaccines
Completed - verified March 2012 - Conditions: Dyskinesia,; Drug-induced
Interventions: Drug: AQW051; Drug: AQW051; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified November 2011 - Conditions: Upper Respiratory Tract Infection; Nasal Congestion; Rhinorrhea; Sneezing
Interventions: Drug: Paracetamol (500 mg)/dimethindene maleate (1 mg)/ phenylephrine hydrochloride (10 mg) tablets; Drug: Paracetamol (500 mg) tablets
Sponsors: Novartis; Novartis; NOVARTIS BIOCIÊNCIAS S.A.
Not yet recruiting - verified April 2012 - Conditions: Adult Lymphocyte Depletion Hodgkin Lymphoma; Adult Lymphocyte Predominant Hodgkin Lymphoma; Adult Mixed Cellularity Hodgkin Lymphoma; Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma; Adult Nodular Sclerosis Hodgkin Lymphoma; Recurrent Adult Hodgkin Lymphoma
Interventions: Drug: panobinostat; Drug: lenalidomide
Sponsors: Ohio State University Comprehensive Cancer Center; Ohio State University Comprehensive Cancer Center; Celgene Corporation; Novartis
Recruiting - verified February 2012 - Condition: Renal Cancer
Intervention: Drug: BEZ235
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Novartis
Recruiting - verified January 2012 - Condition: Neuroendocrine Tumors
Interventions: Drug: Pasireotide; Procedure: Sir Sphere Radioembolization; Drug: Everolimus
Sponsors: Emory University; Emory University; Novartis
Recruiting - verified February 2012 - Conditions: Inoperable Locally Advanced Breast Cancer; Metastatic Breast Cancer (MBC)
Intervention: Drug: BEZ235 + Paclitaxel
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Condition: Renal Transplantation
Interventions: Drug: Basiliximab; Drug: Basiliximab; Drug: Basiliximab
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Condition: Irritable Bowel Syndrome
Interventions: Dietary Supplement: Lactibiane Tolerance; Dietary Supplement: Placebo
Sponsors: Pileje; Pileje
Recruiting - verified February 2012 - Condition: Basal Cell Carcinoma
Intervention: Drug: LDE225
Sponsors: Stanford University; Stanford University; Novartis
Recruiting - verified February 2012 - Condition: Metastatic Renal Cell Cancer
Intervention: Drug: Everolimus
Sponsors: VU University Medical Center; Hans J. van der Vliet, MD, PhD; Dutch Cancer Society; Novartis
Recruiting - verified November 2011 - Conditions: Streptococcal Infection; Gram-positive Bacterial Infection; Bacterial Infection
Interventions: Biological: Group B streptococcus vaccine; Biological: Placebo
Sponsors: Novartis; Novartis; Novartis Vaccines
Recruiting - verified May 2012 - Condition: Meningococcal Disease
Intervention: Biological: MenACWY-CRM
Sponsors: Novartis; Novartis Vaccines; Novartis
Recruiting - verified May 2012 - Conditions: Advanced Solid Tumors; Metastatic Breast Cancer; Metastatic Renal Cell Carcinoma
Intervention: Drug: RAD001 + BEZ235
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Conditions: Hepatitis C; Liver Disease
Interventions: Drug: DEB025 plus peg-IFN alpha 2a and ribavirin fixed duration treatment; Drug: DEB025 plus peg-IFN alpha 2a and ribavirin response guided treatment duration; Drug: Boceprevir plus peg-IFN alpha 2a and ribavirin per label response guided treatment
Sponsors: Novartis; Novartis Pharmaceuticals
Active, not recruiting - verified April 2012 - Condition: Meningococcal Disease
Intervention: Biological: MenACWY-CRM
Sponsors: Novartis; Novartis Vaccines
Recruiting - verified May 2012 - Condition: Hepatic Impairment
Intervention: Drug: Iloperidone
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified February 2012 - Condition: Renal Impairment
Intervention: Drug: AGO178C
Sponsors: Novartis; Novartis Pharmaceuticals
Completed - verified October 2011 - Condition: Erythemato-telangiectatic Rosacea
Interventions: Drug: BFH772 1% ointment; Drug: Vehicle ointment; Drug: Noritate® 1% cream
Sponsors: Novartis; Novartis Pharmaceuticals
Completed - verified April 2012 - Conditions: Solid Tumors; Hepatic Impairment
Intervention: Drug: Dovitinib
Sponsors: Novartis; Novartis
Recruiting - verified November 2011 - Condition: Typhoid Fever
Intervention: Biological: NVGH Vi-CRM
Sponsors: Novartis Vaccines Institute for Global Health; Novartis Vaccines Institute for Global Health
Completed - verified April 2012 - Conditions: Depression; Relapsing-remitting Multiple Sclerosis
Interventions: Drug: Fingolimod plus Venlafaxine; Drug: Fingolimod plus Citalopram; Drug: Fingolimod plus Fluoxetine; Drug: Fingolimod plus Sertraline
Sponsors: Novartis; Novartis
Recruiting - verified November 2011 - Conditions: Meningococcal Disease; Meningococcal Meningitis
Interventions: Biological: Meningococcal C conjugate vaccine; Biological: Meningococcal C conjugate vaccine; Biological: Meningococcal C conjugate vaccine
Sponsors: Novartis; Novartis; Novartis Vaccines
Recruiting - verified March 2012 - Condition: Asthma
Interventions: Drug: QAW039; Drug: Comparator leukotriene receptor antagonist (LRTA); Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Condition: HIV Infection
Interventions: Biological: HIV-1 Tat/delta-V2 Env combined vaccine; Biological: HIV-1 delta-V2 Env vaccine; Biological: HIV-1 Tat vaccine; Biological: HIV-1 Tat vaccine
Sponsors: Istituto Superiore di Sanita; Istituto Superiore di Sanita; Novartis Vaccines
Recruiting - verified September 2011 - Condition: Insulin Resistance
Interventions: Drug: BVS857; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Active, not recruiting - verified September 2011 - Condition: Typhoid Fever
Interventions: Biological: NVGH Vi-CRM197 vaccine; Biological: Pneumococcal conjugate vaccine; Biological: Vi Polysaccharide (PS) vaccine
Sponsors: Novartis Vaccines Institute for Global Health; Novartis Vaccines Institute for Global Health
Active, not recruiting - verified April 2012 - Condition: Myeloma
Interventions: Drug: Panobinostat; Drug: Bortezomib; Drug: Lenalidomide; Drug: Dexamethasone; Behavioral: Symptom Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Novartis
Not yet recruiting - verified March 2012 - Condition: Arterial Hypertension
Intervention:
Sponsors: Stiftung Institut fuer Herzinfarktforschung; Stiftung Institut fuer Herzinfarktforschung; Novartis Pharmaceuticals
Active, not recruiting - verified October 2011 - Conditions: Mild, Moderate,; or Severe Renal Impairment
Intervention: Drug: AFQ056
Sponsors: Novartis; Novartis Pharmaceuticals
Completed - verified October 2011 - Conditions: Kidney Disease; Kidney Failure, Chronic
Interventions: Drug: Aliskiren; Drug: Placebo
Sponsors: Brigham and Women's Hospital; Brigham and Women's Hospital; Novartis
Terminated - verified January 2012 - Condition: Hepatitis B, Chronic
Interventions: Drug: telbivudine (ROADMAP); Drug: Telbivudine (Standard of Care)
Sponsors: Nanfang Hospital of Southern Medical University; Nanfang Hospital of Southern Medical University; Major Science and Technology Special Project of China Eleventh Five-year; Novartis
Recruiting - verified March 2012 - Condition: Uveal Melanoma
Intervention: Drug: AEB071
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified March 2012 - Condition: Sickle Cell Anemia
Intervention:
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified December 2011 - Condition: Gastrointestinal Stromal Tumors
Intervention: Drug: dovitinib
Sponsors: Asan Medical Center; Asan Medical Center
Recruiting - verified September 2011 - Condition: Chronic Central Serous Chorioretinopathy
Intervention: Procedure: half-dose photodynamic therapy
Sponsors: Surugadai Nihon University Hospital; Surugadai Nihon University Hospital; Teikyo University
Completed - verified September 2011 - Conditions: Brain Neoplasms; Central Nervous System Neoplasms
Interventions: Drug: Everolimus; Drug: Sorafenib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Bayer; Novartis
Not yet recruiting - verified February 2012 - Condition: Gastrointestinal Tumor
Interventions: Drug: SOM230C LAR; Drug: FOLFIRI Infusion
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; Novartis
Recruiting - verified February 2012 - Condition: Tinea Pedis
Interventions: Drug: Terbinafine; Drug: Terbinafine Placebo
Sponsors: Novartis; Novartis
Completed - verified March 2012 - Condition: Fragile X Syndrome
Intervention: Drug: AFQ056
Sponsors: Novartis; Novartis
Enrolling by invitation - verified December 2011 - Condition: Safety and Tolerability of Iloperidone
Intervention: Drug: iloperidone (oral tablet)
Sponsors: Novartis; Novartis Pharmaceuticals
Suspended - verified March 2012 - Condition: Acute Gouty Arthritis
Intervention: Drug: Canakinumab 150mg in prefilled syringe
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Conditions: Hypertension; Chronic Kidney Disease; Nephrotic Syndrome
Intervention: Drug: Valsartan (VAL489)
Sponsors: Novartis; Novartis Pharmaceuticals
Completed - verified May 2012 - Condition: Multiple Sclerosis
Intervention: Drug: AIN457
Sponsors: Novartis; Novartis
Recruiting - verified April 2012 - Conditions: Hypertension; Metabolic Syndrome
Intervention: Drug: Aliskerin/Valsartan and Rampiril
Sponsors: University of Michigan Health System; University of Michigan Health System; Novartis Pharmaceuticals
Recruiting - verified September 2011 - Condition: Cachexia
Interventions: Drug: BYM338 active drug; Drug: Placebo
Sponsors: Novartis; Novartis
Recruiting - verified April 2012 - Condition: Hepatic Impairment
Intervention: Drug: afq056
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Conditions: Meningococcal Disease; Meningococcal Meningitis
Intervention: Biological: Serogroup B meningococcal vaccine
Sponsors: Novartis; Novartis; Novartis Vaccines
Completed - verified January 2012 - Condition: HIV Infections
Interventions: Biological: Sub C gp140 Vaccine; Biological: MF59C.1 Adjuvant; Other: Sodium chloride
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Enrolling by invitation - verified April 2012 - Condition: Meningococcal Meningitis
Interventions: Biological: placebo+ Combined Tetanus, Reduced Diphtheria Toxoid Acellular Pertussis Vaccine+Quadrivalent Human Papillomavirus Vaccine; Biological: MenACWY Conjugate Vaccine+Combined Tetanus, Reduced Diphtheria Toxoid,Acellular Pertussis Vaccine +Quadrivalent Human Papillomavirus Vaccine
Sponsors: Novartis; Novartis; Novartis Vaccines
Recruiting - verified April 2012 - Condition: Multiple Sclerosis
Interventions: Drug: Fingoliomod; Drug: other disease-modifying therapy
Sponsors: Novartis; Novartis
Recruiting - verified April 2012 - Conditions: Healthy Volunteers; Atopic Dermatitis; Netherton Syndrome
Interventions: Drug: BPR277 ointment (controlled application); Drug: Placebo (Vehicle); Drug: BPR277 ointment; Drug: Placebo (Vehicle); Drug: BPR277; Drug: Placebo (Vehicle)
Sponsors: Novartis; Novartis
Recruiting - verified November 2011 - Condition: Glioblastoma
Interventions: Drug: BKM120 + temozolomide; Drug: BKM120 +temozolomide with/without radiotherapy
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Condition: Relapsing Remitting Multiple Sclerosis (RRMS)
Interventions: Drug: Fingolimod; Drug: Placebo
Sponsors: Novartis; Novartis
Recruiting - verified December 2011 - Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention: Drug: fingolimod
Sponsors: Novartis; Novartis
Recruiting - verified November 2011 - Condition: Hypertension
Intervention:
Sponsors: Novartis; Novartis
Recruiting - verified May 2012 - Condition: Chronic Gouty Arthritis
Intervention: Biological: canakinumab
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified November 2011 - Condition: Influenza
Intervention: Biological: seasonal influenza vaccine
Sponsors: Novartis; Novartis Vaccines
Completed - verified October 2011 - Conditions: Hypertension; Abdominal Aortic Aneurysm
Interventions: Drug: Aliskiren; Drug: Amlodipine
Sponsors: VU University Medical Center; VU University Medical Center; Novartis
Not yet recruiting - verified September 2011 - Condition: Influenza
Intervention:
Sponsors: Fraser Health; Fraser Health; Novartis Pharmaceuticals
Not yet recruiting - verified August 2011 - Condition: Rheumatoid Arthritis
Interventions: Biological: Placebo to Secukinumab (AIN457); Biological: Secukinumab
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Sporadic Inclusion Body Myositis
Interventions: Biological: BYM338; Biological: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Conditions: Advanced Solid Tumors; Excluding Breast Cancer
Intervention: Drug: TKI258
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Condition: Neurofibromatosis Type II
Intervention: Drug: Everolimus (RAD001) , Afinitor®
Sponsors: New York University School of Medicine; New York University School of Medicine; Novartis Pharmaceuticals; The Children's Tumor Foundation
Recruiting - verified January 2012 - Condition: Hepatic Impairment
Intervention: Drug: RLX030A
Sponsors: Novartis; Novartis Pharmaceuticals
Completed - verified March 2012 - Condition: Acromegaly
Intervention: Drug: Sandostatin LAR
Sponsors: Columbia University; Columbia University; Novartis
Recruiting - verified August 2011 - Condition: Plaque-type Psoriasis
Interventions: Drug: secukinumab 150mg; Drug: secukinumab 10mg/kg i.v. regimen
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified December 2011 - Conditions: Hypertension; Left Ventricular Hypertrophy
Intervention: Drug: valsartan
Sponsors: Mustafa Kemal University; Mustafa Kemal University; Novartis Pharmaceuticals
Completed - verified August 2011 - Condition: Follicular Lymphoma
Interventions: Biological: GP2013; Biological: rituximab
Sponsors: Sandoz; Sandoz; Novartis Pharmaceuticals
Recruiting - verified December 2011 - Condition: Bacterial Meningitis
Intervention: Biological: Meningococcal ACWY conjugate vaccine
Sponsors: Novartis; Novartis; Novartis Vaccines
Completed - verified March 2012 - Conditions: Streptococcal Infections; Gram-Positive Bacterial Infections; Bacterial Infections
Intervention: Biological: Group B streptococcus vaccine
Sponsors: Novartis; Novartis Vaccines
Recruiting - verified May 2012 - Condition: Gout
Intervention:
Sponsors: Minneapolis Veterans Affairs Medical Center; jasvinder singh; Department of Veterans Affairs; Takeda Global Research & Development Center, Inc.; Novartis; Regeneron Pharmaceuticals
Active, not recruiting - verified April 2012 - Condition: Kidney Transplantation
Interventions: Drug: Everolimus; Drug: Myfortic+ Everolimus
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Small Cell Lung Cancer
Intervention: Drug: Topotecan and Pasireotide
Sponsors: South Florida Veterans Affairs Foundation for Research and Education; South Florida Veterans Affairs Foundation for Research and Education; Novartis Pharmaceuticals
Recruiting - verified July 2011 - Condition: Osteogenesis Imperfecta
Interventions: Drug: BPS804; Other: Untreated reference group
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Condition: Hypophosphatasia
Intervention: Drug: BPS804
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Conditions: Neurofibromatosis Type 1; Plexiform Neurofibroma; Neurofibromatoses
Intervention: Drug: RAD001: Everolimus
Sponsors: Assistance Publique - Hôpitaux de Paris; Assistance Publique - Hôpitaux de Paris; Novartis
Recruiting - verified June 2011 - Condition: Atherosclerosis
Interventions: Drug: Aliskiren; Drug: Placebo
Sponsors: Ohio State University; Ohio State University; Novartis
Recruiting - verified August 2011 - Phase I Study of Panobinostat + Bortezomib for Relapsed and/or Refractory Mantle Cell Lymphoma (MCL)Condition: Mantle Cell Lymphoma
Interventions: Drug: Panobinostat; Drug: Bortezomib
Sponsors: Georgia Health Sciences University; Anand Jillella; Novartis Pharmaceuticals
Recruiting - verified January 2012 - Condition: Advanced Gastric Cancer
Intervention: Drug: AUY922 + Trastuzumab
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Haemophilus Influenzae Type B Infection
Intervention: Biological: Haemophilus influenza type b conjugate vaccine
Sponsors: Novartis; Novartis Vaccines
Recruiting - verified February 2012 - Conditions: Transfusion-dependent β-thalassemia Patients; Cardiac Iron Overload
Interventions: Drug: Deferasirox; Drug: Deferasirox + Deferoxamine
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Type 2 Diabetes Mellitus (T2DM)
Intervention: Drug: LIK066 or a matching placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Conditions: Hypertension; Diabetes Mellitus
Interventions: Drug: Aliskiren; Drug: Amlodipine
Sponsors: Hospital Universitario Pedro Ernesto; Hospital Universitario Pedro Ernesto; Novartis
Withdrawn - verified April 2011 - Condition: Alzheimer's Disease
Interventions: Drug: Rivastigmine; Drug: Rivastigmine
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Conditions: Visual Impairment; Macular Edema; Central Retinal Vein Occlusion
Interventions: Drug: Ranibizumad; Other: Dexamethasone Implant + sham injections
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified November 2011 - Conditions: Visual Impairment; Macular Edema; Branch Retinal Vein Occlusion
Interventions: Drug: Ranibizumad; Other: Dexametha sone Implant + sham injections
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified November 2011 - Condition: Lung Transplantation
Interventions: Drug: standard therapy; Drug: Everolimus (RAD001) as add-on
Sponsors: Novartis; Novartis Pharmaceuticals; Crolll Gmbh
Recruiting - verified April 2012 - Condition: Hepatic Impairment
Intervention: Drug: Midostaurin
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Transfusional Hemosiderosis
Intervention: Drug: deferasirox
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Asian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MFConditions: Primary Myelofibrosis (MF); Post-Polycythemia Vera (PV) MF; Post-Essential Thrombocythemia (ET) MF
Intervention: Drug: Ruxolitinib
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Condition: Pulmonary Arterial Hypertension
Intervention: Drug: Imatinib
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Moderate to Severe Plaque-type Psoriasis
Interventions: Biological: secukinumab 150 mg; Drug: If disease relapses patient is treated with secukinumab 150 mg. If disease does not relapse patient is treated with placebo; Biological: secukinumab 300 mg; Biological: If disease relapses patient is treated with secukinumab 300 mg. If disease does not relapse patient is treated with placebo.
Sponsors: Novartis; Novartis
Recruiting - verified April 2012 - Condition: Diabetes Mellitus Type 2
Interventions: Drug: Vildagliptin; Drug: Sitagliptin
Sponsors: Novartis; Novartis
Recruiting - verified May 2012 - Conditions: Osteopenia; Osteoporosis
Interventions: Drug: BPS804; Drug: placebo; Drug: BPS804; Drug: Placebo; Drug: BPS804 dosing frequency 3; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Conditions: Diabetes; Hypertension
Intervention:
Sponsors: Novartis; Novartis
Completed - verified July 2011 - Condition: Chronic Myeloid Leukemia
Intervention: Drug: Nilotinib
Sponsors: Seoul St. Mary's Hospital; Seoul St. Mary's Hospital; Novartis
Active, not recruiting - verified August 2010 - Condition: Chronic Myeloid Leukemia
Intervention: Drug: Nilotinib, Imatinib
Sponsors: Seoul St. Mary's Hospital; Seoul St. Mary's Hospital; Novartis
Recruiting - verified September 2009 - Condition: Gastrointestinal Stromal Tumor
Intervention: Drug: AUY922
Sponsors: Sarah Cannon Research Institute; Sarah Cannon Research Institute; Novartis
Recruiting - verified December 2011 - Condition: Renal Cell Carcinoma
Intervention: Drug: everolimus and bevacizumab
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Novartis Pharmaceuticals
Recruiting - verified March 2012 - Condition: Resectable Pancreatic Adenocarcinoma
Interventions: Drug: LDE-225; Drug: Gemcitabine
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center; Novartis
Recruiting - verified March 2012 - Condition: Psoriatic Arthritis
Interventions: Biological: Secukinumab (75 mg); Biological: Secukinumab (150 mg); Biological: Placebo Comparator
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Condition: Epilepsy
Intervention: Drug: Anti-epileptic drug (AED)
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified February 2012 - Condition: Diffuse Large B-Cell Lymphoma
Intervention: Drug: AEB071
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Pancreatic Fistula
Interventions: Drug: Intraarterial application of Octreotide; Drug: sterile NaCl (sodium chloride) 0,9% solution
Sponsors: St. Josef Hospital Bochum; St. Josef Hospital Bochum
Completed - verified March 2012 - Condition: Leukemia
Intervention: Drug: BKM120
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Novartis
Not yet recruiting - verified May 2012 - Condition: Age Related Macular Degeneration (AMD)
Intervention: Device: Health Management Tool (HMT)
Sponsors: Novartis; Novartis Pharmaceuticals; Carematix, VAS (Vital Art and Science)
Completed - verified February 2012 - Condition: Endometrial Cancer
Intervention: Drug: BKM120
Sponsors: University of Utah; University of Utah; Novartis
Not yet recruiting - verified March 2012 - Condition: Hepatitis C
Interventions: Drug: LCQ908; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Terminated - verified May 2012 - Condition: Metastatic Renal Cell Carcinoma (mRCC)
Intervention: Other: everolimis
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified January 2012 - Condition: Type 2 Diabetes Mellitus
Intervention: Drug: vildagliptin
Sponsors: Novartis; Novartis Pharmaceuticals
Completed - verified August 2011 - Conditions: Dyskinesias; Parkinson Disease; Movement Disorders; Parkinsonian Disorders
Interventions: Drug: AFQ056; Drug: Placebo
Sponsors: Novartis; Novartis
Recruiting - verified April 2012 - Conditions: Idiopathic Myelofibrosis; Post Essential Thrombocythemia Myelofibrosis; Post Polycythemia-Vera Myelofibrosis
Intervention: Drug: panobinostat, ruxolitinib
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified December 2011 - Condition: Advanced Solid Tumor
Intervention: Drug: BYL719
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified November 2011 - Condition: Schnitzler Syndrome
Interventions: Drug: Canakinumab; Drug: Placebo
Sponsors: Charite University, Berlin, Germany; Charite University, Berlin, Germany; Novartis Pharmaceuticals
Recruiting - verified July 2011 - Conditions: Nasal Polyposis; Asthma
Interventions: Drug: Omalizumab; Drug: Placebo
Sponsors: University Hospital, Ghent; University Hospital, Ghent; Novartis Pharma AG, Switzerland
Completed - verified July 2011 - Condition: Retinal Vein Occlusion
Intervention: Drug: ranibizumab
Sponsors: Novartis; Novartis Pharmaceuticals
Active, not recruiting - verified March 2012 - Condition: Chronic Hepatitis
Interventions: Drug: oral antiviral for HBV; Drug: tenofovir disoproxil fumarate
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Conditions: HIV Seronegativity; HIV Preventive Vaccine
Interventions: Biological: MVA-C + gp140/MF59; Biological: MVA-C + gp140/MF59; Biological: DNA-C2 + MVA-C; Biological: DNA-C2 + MVA-C + gp140/MF59
Sponsors: HIV Vaccine Trials Network; HIV Vaccine Trials Network; South Africa AIDS Vaccine Initiative
Recruiting - verified November 2011 - Condition: Pancreatic Cancer
Interventions: Drug: SOM 230 LAR; Drug: Gemcitabine
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: Secukinumab (75 mg); Drug: Secukinumab (150 mg); Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Conditions: Prostate Cancer; Metastatic
Intervention: Drug: BKM120
Sponsors: Duke University; Duke University; Novartis Pharmaceuticals
Recruiting - verified October 2011 - Condition: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Drug: Indacaterol; Drug: Formoterol
Sponsors: Novartis; Novartis Pharmaceuticals
Withdrawn - verified May 2012 - Condition: Islet Cell Tumor
Interventions: Drug: Everolimus; Drug: Pasireotide + Everolimus
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Cushing's Disease
Interventions: Drug: SOM230 LAR 30 mg; Drug: SOM230 LAR 10 mg
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Condition: Healthy
Intervention: Drug: Letrozole
Sponsors: Dr. Reddy's Laboratories Limited; Dr. Reddy's Laboratories Limited
Completed - verified May 2011 - Condition: Healthy
Intervention: Drug: Letrozole
Sponsors: Dr. Reddy's Laboratories Limited; Dr. Reddy's Laboratories Limited
Completed - verified June 2011 - Condition: Kidney Transplant Rejection
Interventions: Drug: everolimus; Drug: cyclosporine
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified April 2012 - Condition: Alzheimer's Disease
Intervention: Drug: rivastigmine patch
Sponsors: Dong-A University; Dong-A University; Novartis Korea Ltd.
Not yet recruiting - verified April 2011 - Conditions: Solid Tumors and Advanced Endometrial Cancer; Endometrial Cancer; Second-line Treatment; VEGF
Intervention: Drug: TKI258
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified December 2011 - Condition: Chronic Myelogenous Leukemia
Intervention: Drug: nilotinib
Sponsors: Novartis; Novartis Pharmaceuticals
Completed - verified June 2011 - Conditions: Hypertension; Stage 2 Hypertension; Diabetes
Interventions: Drug: Valturna + amlodipine; Drug: valturna + placebo; Drug: Valturna + chlorthalidone
Sponsors: Novartis; Novartis
Recruiting - verified May 2012 - Condition: Iron Overload
Intervention:
Sponsors: Children's Hospital Los Angeles; Children's Hospital Los Angeles; Novartis Pharmaceuticals
Completed - verified July 2010 - Conditions: Alpha-1-antitrypsin Deficiency; Liver Cirrhosis
Interventions: Drug: Drug-Carbamazepine (Tegretol XR); Drug: Carbamazepine (Tegretol XR) Placebo
Sponsors: University of Pittsburgh; University of Pittsburgh; Novartis; National Institutes of Health (NIH); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Not yet recruiting - verified January 2012 - Condition: Hepatocellular Carcinoma
Interventions: Drug: everolimus; Drug: everolimus placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Moderate to Severe Plaque-type Psoriasis
Interventions: Drug: secukinumab 150 mg; Drug: secukinumab 150 mg; Drug: placebo to secukinumab 150 mg
Sponsors: Novartis; Novartis Pharmaceuticals
Active, not recruiting - verified May 2012 - Condition: Influenza Vaccine
Interventions: Biological: Agriflu; Biological: Fluad; Biological: Intanza; Biological: Vaxigrip
Sponsors: University of British Columbia; University of British Columbia; PHAC/CIHR Influenza Research Network
Active, not recruiting - verified March 2012 - Conditions: Diabetes; Immunosuppression
Intervention: Procedure: Gastric emptying test
Sponsors: The University of Texas, Galveston; The University of Texas, Galveston; Novartis Pharmaceuticals
Recruiting - verified June 2011 - Condition: Plexiform Neurofibroma Associated With Neurofibromatosis Type 1
Intervention: Drug: Everolimus
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified November 2011 - Conditions: Meningococcal Disease; Meningococcal Meningitis
Intervention: Biological: Meningococcal ABCWY Vaccine
Sponsors: Novartis; Novartis Vaccines
Active, not recruiting - verified May 2012 - Condition: Moderate to Severe Allergic Asthma
Intervention:
Sponsors: Novartis; Novartis Pharmaceuticals; Genentech
Completed - verified June 2011 - Condition: Rabies
Intervention: Biological: Purified Chick Embryo Cell Inactivated Rabies Vaccine
Sponsors: Novartis; Novartis Vaccines
Completed - verified December 2011
 |
Novartis - Database of Clinical Trials by Pharmaceutical Companies |
